Shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) fell sharply during Wednesday’s session after the company reported first-quarter financial results.…
VirTra shares down after reporting worse-than-expected Q1 results with revenue decline of 19% due to delays in federal funding and cost increases from Microsoft contract. CEO anticipates revenue growth with launch of V-XR, CFO sees growth in recurring revenue streams.
Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) rose sharply in today’s pre-market trading after the company reported better-than-expected first-quarter…
VirTra, Inc. (Nasdaq: VTSI) ("VirTra" or the "Company"), a global provider of judgmental use of force training simulators, firearms training simulators for the law enforcement and military markets, today announced a